Organogenesis Holdings Inc.
ORGO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001661181
No open-market purchases or sales by Organogenesis Holdings Inc. insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $166.2M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +16 vs. previous quarter
- 135
- 13F valueReported value at the end of Q2 2026
- $166.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ORGO, Q2 2026
No superinvestor reported holding ORGO at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Organogenesis Holdings Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 (view filing) | Mar 9 | 2 days | Leibowitz Arthur SDirector | PPurchaseClass A Common Stock | +5.00K | $2.68 | +$13.4K | +1.7%291.0K after | |
| Mar 11, 2026 (view filing) | Mar 9 | 2 days | Driscoll Michael JosephDirector | PPurchaseClass A Common Stock | +10.0K | $2.67 | +$26.7K | +4.6%225.7K after | |
| Dec 18, 2025 (view filing) | Dec 16 | 2 days | Nussdorf Glenn HDirector | SSaleClass A Common Stock | −200.0K | $5.14 | −$1.03M | −7.2%2.57M after | |
| Nov 26, 2025 (view filing) | Nov 24-26 | 2 days | Nussdorf Glenn HDirector, 10% Owner | SSaleClass A Common Stock | −300.0K | $5.31 | −$1.59M | −9.8%2.77M after | 3 lots |
| Nov 3, 2025 (view filing) | May 14-15 | 173 daysLate | Nussdorf Glenn HDirector, 10% Owner | PPurchaseClass A Common Stock | +358.5K | $3.06 | +$1.10M | New position358.5K after | 2 lots |
| Nov 3, 2025 (view filing) | Jun 9-10 | 147 daysLate | Nussdorf Glenn HDirector, 10% Owner | SSaleClass A Common Stock | −22.8K | $3.55 | −$80.8K | −6.4%335.7K after | 2 lots |
| Jun 6, 2025 (view filing) | Jun 4-6 | 2 days | Freedman LoriChief Admin. and Legal Officer | PPurchaseClass A Common Stock | +252.3K | $2.88 | +$725.7K | +42.5%846.5K after | 3 lots |
| Mar 6, 2025 (view filing) | Mar 4 | 2 days | Driscoll Michael JosephDirector | SSaleClass A Common Stock | −25.0K | $5.10 | −$127.5K | −13.0%166.9K after | |
| Dec 16, 2024 (view filing) | Dec 13-16 | 3 days | Gillheeney Gary S.President and CEO | SSaleClass A Common Stock | −61.2K | $3.37 | −$206.4K | −2.0%3.04M after | 2 lots |
| Dec 12, 2024 (view filing) | Dec 10-12 | 2 days | Gillheeney Gary S.President and CEO | SSaleClass A Common Stock | −259.3K | $3.62 | −$940.1K | −7.7%3.10M after | 3 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Organogenesis Holdings Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 11,721,609 | $28.5M | 0.00% | +104,814+0.9% | Added |
| Soleus Capital Management, L.P. | 10,140,951 | $24.6M | 0.85% | +55,000+0.5% | Added |
| BlackRock, Inc. | 7,249,528 | $17.6M | 0.00% | +2,349,777+48.0% | Added |
| Assenagon Asset Management S.A. | 3,935,904 | $9.56M | 0.01% | +1,967,952+100.0% | Added |
| Dimensional Fund Advisors LP | 3,050,297 | $7.41M | 0.00% | +159,291+5.5% | Added |
| AQR Capital Management LLC | 3,011,753 | $7.32M | 0.00% | +2,130,036+241.6% | Added |
| Vanguard Capital Management LLC | 2,905,919 | $7.06M | 0.00% | +5,103+0.2% | Added |
| D. E. Shaw & Co., Inc. | 2,888,313 | $7.02M | 0.00% | +590,339+25.7% | Added |
| Geode Capital Management, LLC | 1,935,554 | $4.70M | 0.00% | +151,590+8.5% | Added |
| Deutsche Bank AG | 1,706,186 | $4.15M | 0.00% | +5050.0% | Added |